belzutifan 治疗晚期实体瘤的Ⅰ期 LITESPARK-001 研究:透明细胞肾细胞癌队列延长至 41 个月随访
LITESPARK-001 是一项开放标签、3+3 剂量递增后扩展的Ⅰ期研究,入组 7 个中心的晚期透明细胞肾细胞癌患者,接受 belzutifan 120 mg 口服每日一次。中位随访 41.2 个月时,55 例中 14 例(25%)达到客观缓解,中位缓解持续时间未达到,安全性可接受。
要点
- 55 例经治晚期透明细胞肾细胞癌患者中 14 例(25%)达到客观缓解,中位缓解持续时间未达到。
- 中位随访 41.2 个月(范围 38.2-47.7),belzutifan 单药显示持久抗肿瘤活性。
- 53 例(96%)报告研究者判定与治疗相关的不良事件,22 例(40%)为 3 级,无 4 级或 5 级治疗相关不良事件。
核心结论
- 中位随访 41.2 个月后,belzutifan 单药在晚期透明细胞肾细胞癌患者中显示持久的抗肿瘤活性和可接受的安全性。
研究设计与样本
- LITESPARK-001 为正在进行的开放标签研究,采用 3+3 剂量递增设计后进入扩展期,患者来自 7 个中心。
- 患者接受 belzutifan 120 mg 口服每日一次,直至疾病进展、不可接受毒性或患者退出,数据截止日期为 2021 年 7 月 15 日。
- 主要终点为确定最大耐受剂量和/或Ⅱ期推荐剂量,次要终点包括研究者按 RECIST v1.1 评估的客观缓解率和缓解持续时间及安全性。
主要发现
- 中位随访 41.2 个月(范围 38.2-47.7),患者既往接受中位 3 种(范围 1-9)全身治疗。
- 55 例患者中 14 例(25%)达到客观缓解,中位缓解持续时间未达到(范围 3.1+ 至 38.0+ 个月)。
- 研究者判定与治疗相关的不良事件见于 53 例(96%),22 例(40%)发生 3 级治疗相关不良事件,最常见为贫血(n=13;24%)和缺氧(n=7;13%)。
- 未发生 4 级或 5 级治疗相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accumulation of the HIF-2α transcription factor is an oncogenic event implicated in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). In the phase I LITESPARK-001 study, the first-in-class HIF-2α inhibitor belzutifan demonstrated antitumor activity and an acceptable safety profile for pretreated patients with advanced ccRCC. Updated data with additional follow-up of > 40 months are presented. METHODS: LITESPARK-001 is an ongoing open-label study with a 3 + 3 dose-escalation design followed by an expansion phase. Patients with ccRCC enrolled at 7 sites received belzutifan 120 mg orally once daily until disease progression, unacceptable toxicity, or patient withdrawal. The data cutoff date was July 15, 2021. The primary end point was identifying the maximum tolerated dose and/or the recommended phase II dose. Secondary end points included objective response rate (ORR) and duration of response (DOR) per RECIST v1.1 by investigator assessment and safety. RESULTS: Median follow-up was 41.2 months (range, 38.2-47.7). Patients received a median of 3 (range, 1-9) prior systemic therapies. Of 55 patients, 14 (25 %) achieved an objective response. Median DOR was not reached (range, 3.1 + to 38.0 + months). Adverse events (AEs) attributed to study treatment by investigator assessment were reported in 53 patients (96 %). 22 patients (40 %) had grade 3 treatment-related AEs; the most common were anemia (n = 13; 24 %) and hypoxia (n = 7; 13 %). No grade 4 or 5 treatment-related AEs occurred. CONCLUSION: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety. CLINICALTRIALS: gov. NCT02974738.
引用
- Jonasch E, Bauer TM, Papadopoulos KP, et al. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2023. PMID: 38008031. doi:10.1016/j.ejca.2023.113434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。